Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00893763 · ClinicalTrials.gov registry record · Phase 2
Strategies To Prevent Pneumonia 2 (SToPP2)
A Phase 2 study, sponsored by University of South Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 314
- Enrollment target
NCT00893763: Completed Phase 2 study, sponsored by University of South Florida.
NCT00893763 is a Phase 2 study that has completed, run by University of South Florida. The registered enrollment target is 314 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (136% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00893763, a Phase 2 study, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 314 participants
- Enrollment target
Study Summary
Ventilator-associated pneumonia (VAP) is a serious complication in mechanically ventilated critically ill patients. The intervention tested in this project (swabbing the mouth with chlorhexidine before the endotracheal tube is inserted) could reduce the risk of ventilator-associated pneumonia.
Primary Outcome
Change between post-intervention CPIS and baseline CPIS. Serial prospective evaluation of VAP risk. 6 elements of CPIS (tracheal secretions, temperature, white blood count, oxygenation, chest radiograph, and tracheal aspirate culture) summed to yield total score of 0-12 daily; higher score reflects greater likelihood of VAP.
Interventions
- PROCEDURE Control
- PROCEDURE Pre-intubation CHX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2008-09 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
What the finished NCT00893763 record still lists
NCT00893763 is an interventional study that assigns participants to a tested intervention. The registered 314 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (136% higher).
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT00893763 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00893763 about?
NCT00893763 is a clinical study titled "Strategies To Prevent Pneumonia 2 (SToPP2)". Ventilator-associated pneumonia (VAP) is a serious complication in mechanically ventilated critically ill patients. The intervention tested in this project (swabbing the mouth with chlorhexidine before the endotracheal tube is inserted) could reduce the risk of ventilator-associated pneumonia.
What is the current status of trial NCT00893763?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 314 participants. The study started on 2008-09. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00893763?
The interventions under investigation include: Control (PROCEDURE), Pre-intubation CHX (PROCEDURE).
Who is sponsoring clinical trial NCT00893763?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00893763's enrollment target sits among peer trials
314 159th of 2000 higher than 1,840 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03866382 · 314 participants · Phase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- NCT04500756 · 314 participants · Phase 2
Limiting AAA With Metformin (LIMIT) Trial
- NCT06167746 · 314 participants · Phase 3
iCare4Me Transitions
- NCT06883097 · 314 participants · NA
Quitting Matters Human Immunodeficiency Virus Hybrid Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia